- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: VG.
Displaying page 1 of 5.
EudraCT Number: 2013-001405-90 | Sponsor Protocol Number: GS-LHON/CLIN/01 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:GENSIGHT-BIOLOGICS | |||||||||||||
Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations... | |||||||||||||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003854-99 | Sponsor Protocol Number: CLL17 | Start Date*: 2021-06-11 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patie... | |||||||||||||
Medical condition: Patients with previously untreated CLL requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001235-27 | Sponsor Protocol Number: AVXS-101-CL-101 | Start Date*: 2020-04-06 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101 | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-021756-26 | Sponsor Protocol Number: SOMAQ | Start Date*: 2010-11-08 |
Sponsor Name:VG Region, Sahlgrenska sjukhuset, Hudkliniken, Göteborg | ||
Full Title: Behandlingseffekt av UV ljus jämfört med peroralt D vitamin på D-vitaminnivån hos somaliska kvinnor | ||
Medical condition: - Studera effekten på serum vitamin D-nivåerna före och efter vitamin D behandling av vuxna somaliska kvinnor boende i Sverige. - Jämföra serum vitamin D-nivåerna mellan behandling med peroralt vi... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006781-21 | Sponsor Protocol Number: COAV101A12308 | Start Date*: 2022-10-31 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) DK (Trial now transitioned) ES (Ongoing) GR (Prematurely Ended) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020047-12 | Sponsor Protocol Number: P090202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne | |||||||||||||
Medical condition: Enfants atteints de dystrophie de Duchenne | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002739-32 | Sponsor Protocol Number: UF9439 | Start Date*: 2014-11-12 | |||||||||||
Sponsor Name:CHU de Montpellier | |||||||||||||
Full Title: COLIN Intérêt de la COLchicine dans la prise en charge de l’INfarctus aigu du myocarde avec activité inflammatoire importante. -Etude pilote | |||||||||||||
Medical condition: Infarctus du myocarde aigu (IFM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002502-75 | Sponsor Protocol Number: P-pVAC-SARS-CoV-2 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults | |||||||||||||
Medical condition: healthy subjects obtaining a potential vaccine for COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005968-24 | Sponsor Protocol Number: Vx-001-201 | Start Date*: 2013-01-23 | |||||||||||
Sponsor Name:Vaxon Biotech | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HL... | |||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GR (Prematurely Ended) ES (Ongoing) IT (Ongoing) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002097-51 | Sponsor Protocol Number: FLT190-01 | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Freeline Therapeutics Ltd | |||||||||||||
Full Title: A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry disease | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004981-16 | Sponsor Protocol Number: 1991-201-008 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Editas Medicine, Inc. | |||||||||||||
Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen... | |||||||||||||
Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000095-38 | Sponsor Protocol Number: AVXS-101-CL-303 | Start Date*: 2020-03-18 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous ... | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-002979-34 | Sponsor Protocol Number: LTFU-ABO-102 | Start Date*: 2020-05-18 | |||||||||||
Sponsor Name:Abeona Therapeutics Inc | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) | |||||||||||||
Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progress... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003431-29 | Sponsor Protocol Number: MGT012 | Start Date*: 2019-06-24 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: An open label, multi-centre, Phase I/II dose escalation trial of an adeno-associated virus vector (AAV2/8-hG1.7p.coCNGA3) for gene therapy of children with achromatopsia owing to defects in CNGA3 | |||||||||||||
Medical condition: Achromatopsia caused by mutations in the CNGA3 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018277-31 | Sponsor Protocol Number: AOI/2009/VT-03 | Start Date*: 2010-02-18 |
Sponsor Name:CHU de Nîmes | ||
Full Title: EVALUATION DU RETENTISSEMENT PSYCHIATRIQUE, CARDIOVASCULAIRE ET SUR LA QUALITE DE VIE DE L’ HORMONOTHERAPIE FREINATRICE DANS UNE COHORTE DE PATIENTS THYROIDECTOMISES POUR CARCINOME THYROIDIEN PAPI... | ||
Medical condition: Thyroidectomie pour carcinome papillaire différencié | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005063-28 | Sponsor Protocol Number: Emend2 | Start Date*: 2013-10-02 |
Sponsor Name:University of Gothenburg | ||
Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant | ||
Medical condition: End stage renal disease under treatment with peritoneal dialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003678-28 | Sponsor Protocol Number: AVXS-101-CL-102 | Start Date*: 2020-09-15 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting but Non- Ambulatory Patients with Spinal Muscular Atrophy | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-000077-83 | Sponsor Protocol Number: SRP-9001-101 | Start Date*: 2022-11-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: Systemic gene delivery Phase I/IIa clinical trial for Duchenne muscular dystrophy using rAAVrh74.MHCK7.micro-dystrophin (microDys-IV-001) | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005032-30 | Sponsor Protocol Number: FLT201-01 | Start Date*: 2023-03-13 | ||||||||||||||||
Sponsor Name:Freeline Therapeutics Limited | ||||||||||||||||||
Full Title: A Phase 1/2, open-label, safety, tolerability and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (Galileo-1) | ||||||||||||||||||
Medical condition: Type 1 Gaucher Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000078-27 | Sponsor Protocol Number: SRP-9001-102 | Start Date*: 2022-11-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001 | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
